A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia
Sponsor: Cerevel Therapeutics, LLC
This PHASE2 trial investigates Early Course Schizophrenia Spectrum Disorder and is currently completed. Cerevel Therapeutics, LLC leads this study, which shows 14 recorded versions since 2021 — indicating substantial longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Status Flow
Change History
14 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE2
Phase: PHASE1/PHASE2 → PHASE2
-
Apr 2025 — Nov 2025 [monthly]
Completed PHASE1/PHASE2
-
Feb 2025 — Apr 2025 [monthly]
Completed PHASE1/PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
▶ Show 9 earlier versions
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2023 — Jun 2024 [monthly]
Recruiting PHASE1_PHASE2
-
May 2023 — Jul 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2022 — May 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2021 — Sep 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2021 — Sep 2021 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Apr 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Aug 2020 — Dec 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Cerevel Therapeutics, LLC
- Columbia University
- National Institute of Mental Health (NIMH)
- State University of New York Stony Brook
- University of Pennsylvania
- Yale University
For direct contact, visit the study record on ClinicalTrials.gov .